- Poster presentation
- Open Access
Clinical depiction, treatment and long term follow up characterization of a group of enthesitis related arthritis - juvenile idiopathic arthritis patients from a spanish pediatric tertiary hospital
© Baldizon et al; licensee BioMed Central Ltd. 2014
- Published: 17 September 2014
- Juvenile Idiopathic Arthritis
- Ethic Committee Approval
- Juvenile Idiopathic Arthritis Patient
Enthesitis related arthritis (ERA) is a subtype of Juvenile Idiopathic Arthritis (JIA) that affects children >6 years of age. It presents with enthesitis, uveitis, peripheral and axial arthritis. It´s one of the less frequent subtypes of JIA. Data is scarse involving follow up and outcomes.
Describe a case series of JIA-ERA patients of a Spanish cohort in a tertiary pediatric hospital. Report response to oral (OR) and subcutaneous (SC) methotrexate (MTX) in insufficient/non-responders to NSAID/intra-articular steroid infiltrations in these patients. Relate the persistence of symptoms on follow-up and course of treatment.
Retrospective and observational.Inclusion criteria: Edmonton classification criteria for ERA-JIA. Variables: age, sex, HLA-B27, date and delay of diagnosis, onset of symptoms, classification, start/finish of date of OR MTX, start/finish date of MTX SC, date of start of biologic treatment (as a variable of MTX inefficacy). Articular activity: number of swollen joints (NSJ) and number of painful joints (NPJ). Prospective data will be collected starting January 2014 of all ERA-JIA patients visited in our Unit. Local ethics committee approval was acquired.
NPJ at onset
NPJ at end of follow up
NSJ at onset
NSJ at end of follow up
Patients had a mean age of 11 years at time of diagnosis, are male, HLA-B27 positive and have low level joint activity. The majority of patients that started OR MTX switched to SC MTX due to inefficacy or insufficient response, with a mean weekly dose of 15mg/weekSC MTX. The rate of side effects was low (<10%). Several patients required active treatment (DMARD/biologic) after 4 years of follow-up. Our findings should be taken with a grain of salt as this analysis is preliminary and we will be completing data from all of our JIA-ERA patients in coming months.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.